Login
Create Account

Powerpack

Unlock full stockrow access for only $7.9/month and boost yourself as an investor.

Watchlist

Keep track of companies that you follow and research.

10 Years of Data

Full access to our data with predictions and indicators that we calculate daily.

Screener

Full access to our screener with tons of custom values and customizable email notifications.

XLS Exports

Excel export of financials and screeners you define and save.

Veracyte, Inc. VCYT

Healthcare — Diagnostics & Research
Cash Flow Champion (3y)
Growth Flags show if company had growth for consecutive years

We limit data available in the Overview Report for users who do not have Powerpack

Get access to target analyst prices, predictions, compound annual growth rates and more than four years of historical data.
Register an account and get your Powerpack now or Login

Insider Decisions

Total sells
21.17
in millions of $
Nov 25 Feb 26 May 26 Aug 26
Buy — — — — — — — — — — — —
Sell 1 8 6 — — 5 — 3 5 — — 5
Insider Ownership
1.33%

Capital & Financial Ratios

Market Cap
3,260.00
Revenue
561.90
Net Income
114.48
Free Cash Flow
165.99
Net Debt
(485.23)
Current Ratio
9.16
Debt/Equity
0.00
P/E ratio
27.64
P/S ratio
5.66
P/B ratio
2.29
Past 5Y EPS Growth
(10.52%)
This Y EPS Growth
7.53%
Next Y EPS Growth
1.94%
Next 5Y EPS Growth
5.29%
in millions of $

Dividends

Payout Ratio
0.00
Annual Dividend Rate
—
Annual Dividend Yield
—
total individual payouts
2025 ‡‡‡
2024 ‡‡‡
2023 ‡‡‡
2022 ‡‡‡
2021 ‡‡‡
2020 ‡‡‡
2019 ‡‡‡
2017 ‡‡‡
predictions in italic, special payouts not included in total or ratios

Assets vs Liabilities

2023 2024 2025 Q'26
Cash 216.45 289.44 412.89 485.23
Receivables 40.38 46.53 44.66 54.18
Inventory 16.13 21.75 20.55 22.66
Other — — — —
285.62 372.27 488.38 574.78
2023 2024 2025 Q'26
Payables 12.94 8.63 4.59 8.02
ST’ Debt — — — —
Other 2.76 17.00 1.33 0.66
61.24 78.63 59.94 62.74
in millions of $

Compound Annual Growth

10y 5y 3y
Sales ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Cash Flow ‡‡‡ ‡‡‡ ‡‡‡‡‡
Earnings ‡‡‡ ‡‡‡ ‡‡‡
Book Value ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡

Revenue

Mar Jun Sep Dec Year
’26 139.07 150.32 — —
—
’25 114.47 130.16 131.87 140.64
517.15
’24 96.84 114.43 115.86 118.63
445.76
’23 82.42 90.32 90.11 98.20
361.05
’22 67.78 72.86 75.59 80.30
296.54
’21 36.70 55.11 60.37 67.34
219.51
’20 31.12 20.70 31.12 34.54
117.48
in millions of $

Operating Cash Flow

Mar Jun Sep Dec Year
’26 35.22 45.83 — —
—
’25 5.36 33.61 44.76 52.58
136.31
’24 (8.97) 29.58 29.96 24.52
75.10
’23 (2.17) 16.67 14.17 15.55
44.22
’22 (8.87) (0.36) 7.03 9.74
7.54
’21 (40.56) 1.89 (1.39) 8.45
(31.62)
’20 (5.30) (8.42) 1.75 2.26
(9.71)
in millions of $

Free Cash Flow

Mar Jun Sep Dec Year
’26 32.25 42.97 — —
—
’25 3.54 32.32 41.97 48.80
126.63
’24 (11.10) 26.81 27.72 20.38
63.81
’23 (3.16) 13.00 11.37 13.06
34.26
’22 (11.32) (2.87) 5.31 7.87
(1.01)
’21 (41.76) 0.36 (3.20) 7.61
(37.00)
’20 (5.97) (9.07) 1.12 1.37
(12.55)
in millions of $

EPS

Mar Jun Sep Dec Year
’26 0.35 0.31 — —
—
’25 0.09 (0.01) 0.24 0.51
0.82
’24 (0.02) 0.07 0.19 0.06
0.31
’23 (0.11) (0.12) (0.41) (0.39)
(1.02)
’22 (0.20) (0.13) (0.12) (0.05)
(0.51)
’21 (0.66) (0.13) (0.20) (0.15)
(1.11)
’20 (0.24) (0.22) (0.08) (0.14)
(0.66)

Target Price Range

High
‡‡‡‡‡
‡‡‡‡
Average
‡‡‡‡‡
‡‡‡‡
Low
‡‡‡‡‡
‡‡‡‡

Recommendation Rating

1.4
1
Buy
2
3
Hold
4
5
Sell
2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028
‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡‡ 14.85 19.52 18.61 22.61 — — —
Low Price
‡‡‡‡ ‡‡‡ ‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 42.95 30.52 46.00 50.71 — — —
High Price
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 787 815 824 755 — — —
Employees
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.38 0.44 0.54 0.68 — — —
Revenue/Emp
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 296.54 361.05 445.76 517.15 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 59.24% 63.62% 66.88% 70.10% — — —
Gross Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (36.43) (76.61) 25.74 68.20 ‡‡‡‡‡ — —
EBT
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (12.28%) (21.22%) 5.78% 13.19% ‡‡‡ ‡‡‡ ‡‡‡
EBT Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (36.56) (74.40) 24.14 66.35 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Net Income
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 25.93 26.72 23.11 18.15 — — —
Depreciation
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 4.14 4.97 5.83 6.58 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (0.51) (1.02) 0.32 0.84 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡
Earnings/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.11 0.61 0.98 1.73 ‡‡‡‡ — —
Cash Flow/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (0.12) (0.14) (0.15) (0.12) ‡‡‡ ‡‡‡ ‡‡‡
Capex/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (0.01) 0.47 0.83 1.61 — — —
Free CF/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 15.03 14.37 15.38 16.66 ‡‡‡‡‡ — —
Book Value/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 71.55 72.64 76.49 78.58 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Shares
‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ 0.00 0.00 123.75 50.12 ‡‡‡‡ ‡‡‡‡ ‡‡‡‡
PE Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 5.47 5.51 6.79 6.40 ‡‡‡ ‡‡‡ ‡‡‡
PS Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 1.51 1.91 2.58 2.53 ‡‡‡ ‡‡‡ ‡‡‡
PB Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 4.91 4.95 6.18 5.63 ‡‡‡‡ ‡‡‡‡ ‡‡‡‡
EV/Sales
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (1,436.62) 52.19 43.15 22.98 — — —
EV/FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 7.54 44.22 75.10 136.31 ‡‡‡ ‡‡‡ ‡‡‡
Op' Cash Flow
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (8.55) (9.96) (11.29) (9.68) ‡‡‡‡‡ ‡‡‡‡‡ —
Capex
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (1.01) 34.26 63.81 126.63 ‡‡‡‡‡ — —
FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 186.02 224.38 293.63 428.44 — — —
Working Cap'
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 15.00 — — — — — —
Total Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (163.85) (216.45) (289.44) (412.89) — — —
Net Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 1,075.20 1,044.10 1,175.97 1,309.58 — — —
Sh' Equity
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (3.12%) (6.55%) 2.00% 4.90% ‡‡‡‡ — —
ROA
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (2.82%) (6.48%) 1.14% 4.03% — — —
ROIC
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (3.37%) (7.02%) 2.17% 5.34% ‡‡‡‡‡ — —
ROE
predictions in italic, sparklines do not include predictions

Analyst Commentary (Summary)

Veracyte, Inc. (VCYT), a frontrunner in genomic cancer diagnostics, has staged a dramatic turnaround, achieving its first meaningful profitability in 2024 after years of losses, propelled by explosive revenue growth—a 27% CAGR from $65 million in 2016 to $446 million in 2024. Key acquisitions like Decipher Biosciences and HalioDx expanded its oncology portfolio, boosting test volumes for flagship products like Afirma and Decipher, while operational efficiency soared with revenue per employee up 80% and gross margins expanding 10 points to 67%. Analyst forecasts project sustained momentum, with revenue growing at 19% CAGR through 2027 to $636 million and EPS surging 203% to $0.97, underpinned by margin gains and precision medicine tailwinds from an aging population.

Yet caution tempers the optimism: elevated valuations (forward PE at 37x by 2027, EV/FCF 43x) price in flawless execution amid a competitive landscape with Illumina and Guardant, volatile reimbursements, and persistent share dilution (165% increase since 2016). Heavy insider selling—over $10.5 million from C-suite executives in late 2024 and 2025, with zero buys—signals potential profit-taking or hidden concerns, despite a fortified balance sheet featuring $1.18 billion in equity and robust free cash flow.

Stock volatility mirrors this duality, rewarding 2024 profitability with a 147% rally from 2023 lows but lagging 2021 peaks, trading at a growth discount yet vulnerable to execution slips, recessions curbing procedures, or margin erosion. Analysts see 20-65% upside, but prudence dictates monitoring Q1 2026 earnings for cash flow validation—making VCYT a speculative hold for those balancing growth allure against downside risks.

Read full commentary →

Veracyte, Inc. (VCYT) Latest News

News by impact score

Fine-tune

14 Sep

4 , 4:05 PM
Veracyte acquires Convergent Genomics, expanding its urology diagnostics portfolio with a urinary tumor DNA testing platform. Acquisition adds urinary tumor DNA testing platform and expands Veracyte urology portfolio.

26 Aug

3 , 10:17 AM
Veracyte (VCYT) stock faces evaluation on whether it merits addition to portfolios now, weighing recent performance metrics, growth outlook, and market positioning against sector peers. Stock suitability analysis may shift near-term investor sentiment around VCYT without altering core operations or long-term trajectory.

31 Jul

4 www.marketbeat.com, 10:03 PM
Veracyte Q2 earnings call highlighted revenue growth from Afirma and Decipher tests, expanded test adoption, and positive 2023 outlook amid ongoing commercialization efforts. Q2 earnings details and strategic updates directly shape near-term financial expectations and investor positioning for the company.

4 transcript , 1:03 AM
Veracyte reports record Q2 2026 revenue in earnings call alongside new strategic product launches. Record revenue and strategic launches indicate major positive shifts in Veracyte's market position and growth prospects.

3 , 6:06 AM
Veracyte raised its 2026 revenue guidance, prompting questions on whether the stock is now fully valued after the update. Guidance raise signals improved outlook that may lift near-term sentiment and valuation metrics but does not indicate transformative change.

30 Jul

4 , 4:05 PM
Veracyte, Inc. (VCYT) announced its second quarter 2026 financial results. Quarterly earnings releases typically drive immediate stock price movements and reshape near-term investor outlook for Veracyte.

3 , 6:00 PM
Veracyte (VCYT) Q2 earnings and revenues surpassed estimates. Q2 earnings and revenue beat signals stronger financial performance than expected.

3 , 9:17 AM
Veracyte (VCYT) stock rises after the company raised its guidance and beat earnings expectations. Upward guidance revision and earnings beat typically produce moderate short-term gains in stock price and sentiment.

23 Jul

3 , 10:00 AM
Veracyte (VCYT) Q2 earnings expected to decline. Expected Q2 earnings decline signals potential negative pressure on Veracyte financial results and market valuation.

8 Jul

3 , 12:00 PM
Veracyte (VCYT) upgraded to Strong Buy rating. Analyst upgrade to Strong Buy may lift near-term investor sentiment and share price.

2 Jul

4 , 2:12 PM
Veracyte stock surged 117% over the past year on positive business momentum and investor interest in its diagnostic tests. Strong one-year stock rally signals major gains in operations and market position that can reshape investor outlook.

16 Jun

3 , 8:00 AM
Veracyte stock surges as CEO attributes success to core strategies and execution. CEO comments on success may lift short-term sentiment without altering fundamentals.

3 , 8:00 AM
Veracyte stock surged on strong genomic diagnostics performance, with CEO citing proprietary tests, commercial execution and expanding indications as core growth drivers. CEO commentary on existing momentum can lift near-term sentiment but does not announce new products, approvals or financial results.

1 Jun

4 Business Wire, 7:30 AM
Veracyte launches the Prosigna Breast Test for commercial use in the U.S. Prosigna launch directly expands Veracyte's U.S. breast cancer diagnostics revenue and market reach.

30 May

4 Business Wire, 8:00 AM
Veracyte's Decipher Prostate Test identifies which metastatic prostate cancer patients benefit from added chemotherapy according to ENZAMET Trial results. ENZAMET Trial validation expands Decipher test clinical use in metastatic prostate cancer and supports Veracyte revenue growth.

29 May

4 Business Wire, 3:15 PM
Veracyte's Prosigna test identifies high-risk breast cancer patients who can safely avoid chemotherapy based on practice-changing evidence from the landmark OPTIMA trial. Positive OPTIMA trial results validate Prosigna test utility and will drive higher adoption plus revenue growth for Veracyte.

25 May

3 Zacks, 11:19 AM
Veracyte stock rose 65.8% over the past year on the back of operational and market factors lifting investor sentiment and company valuation. Year-long stock surge reflects noticeable but not transformative gains in Veracyte market performance and positioning.

23 May

4 Simply Wall St., 1:11 PM
Veracyte reports Phase III success for Prosigna and Decipher cancer tests, triggering fresh valuation analysis for VCYT amid improved clinical data and potential market gains. Phase III trial wins for core diagnostic products strengthen Veracyte pipeline and competitive stance in oncology testing.

21 May

3 , 6:00 PM
Results from the OPTIMA trial, set for presentation at ASCO, offer new evidence backing Veracyte's Prosigna test to guide chemotherapy decisions for breast cancer patients. Supportive OPTIMA trial data on Prosigna strengthens clinical positioning and may incrementally lift adoption without immediate major revenue shifts.

15 May

4 Business Wire, 9:00 AM
Veracyte, Inc. secures Medicare coverage for its TrueMRD monitoring test, enabling reimbursement for detecting minimal residual disease in muscle-invasive bladder cancer patients post-treatment. Medicare coverage expands reimbursement access for TrueMRD, driving adoption, revenue growth, and competitive positioning in oncology diagnostics.

14 May

3 Simply Wall St., 7:52 AM
Veracyte's statutory profit understates true earnings strength, as adjusted metrics reveal robust revenue growth, margin expansion, and operational improvements despite one-off charges. Positive earnings reframing highlights underlying financial strength, moderately boosting investor sentiment and performance outlook.

8 May

4 www.fool.com, 1:11 AM
Veracyte Inc. (VCYT) stock surged over 30% this week after the company reported strong Q3 results, including 29% revenue growth to $114 million, beat analyst expectations, raised full-year guidance, and announced positive clinical data for its Decipher Prostate test. Exceptional earnings beat, raised guidance, and key product validation drive significant positive shift in market performance and investor sentiment.

7 May

4 Simply Wall St., 3:19 PM
Veracyte, Inc. (VCYT) beat earnings expectations. Analysts predict positive future performance and share outlook on next steps. Beating earnings expectations combined with analysts' forward-looking views signals significant positive impact on financial trajectory and investor sentiment.

6 May

4 www.marketbeat.com, 12:08 AM
Veracyte reported Q1 revenue of $114.5 million, up 18% year-over-year and 24% in testing volume. Adjusted EPS hit $0.31, surpassing estimates. Full-year guidance raised to $470-473 million revenue and $64-66 million adjusted EBITDA, driven by Decipher and Afirma growth. Earnings beat and raised guidance indicate strong growth momentum, likely boosting investor sentiment and stock performance.

5 May

4 Zacks, 8:30 PM
Veracyte (VCYT) beat Q1 earnings and revenue estimates. Beating Q1 earnings and revenue estimates boosts financial performance and investor sentiment significantly.

4 app.moby.co, 8:18 PM
Veracyte, Inc. (VCYT) Q1 2026 earnings call summary details financial results, revenue growth, operational updates, product pipeline progress, and forward guidance. Quarterly earnings summaries reveal financial health, guidance, and strategic shifts that drive stock volatility and long-term investor confidence.

4 transcript www.fool.com, 6:09 PM
Veracyte (VCYT) Q1 2026 earnings transcript details the company's first-quarter financial results, operational updates, and forward-looking guidance. Q1 2026 earnings transcript discloses financial performance, strategic updates, and guidance that significantly shape VCYT's future trajectory and market perception.

4 Business Wire, 4:05 PM
Veracyte, Inc. (VCYT) announced first quarter 2026 financial results. Quarterly earnings announcements significantly influence financial performance and investor sentiment for VCYT.

4 Zacks, 9:55 AM
Wall Street analysts forecast Veracyte (VCYT) stock could surge 39.16%, based on consensus price targets exceeding current levels. Analysts' 39.16% upside target signals major positive shift in investor sentiment and potential stock trajectory alteration.

3 May

3 Simply Wall St., 3:13 PM
Veracyte (VCYT) valuation analyzed as new Decipher Bladder and Prostate data heads to AUA 2026 presentation. New Decipher Bladder and Prostate data at AUA 2026 could moderately enhance Veracyte's urology diagnostics positioning and investor sentiment.
© 2016–2026 stockrow.com Terms and Conditions Indicators Contact Us